Multiple PD-1/PD-L1 inhibitors have been shown to significantly improve overall survival (OS) and progression-free survival (PFS) in NSCLC patients (7–10), and have been recommended by national and international guidelines as first- or second-line standard treatment options for NSCLC (11–13). This evidence concerns the gene CD274 and non-small cell lung carcinoma.